Articles from OM1

OM1, a real-world evidence generation company and the leading AI outcomes platform, presented its role in the landmark study that supported FDA approval of Hologic's Aptima HPV Assay for primary cervical cancer screening at the Medical Device Innovation Consortium Evidence Summit on May 5, 2026. The approval, announced by Hologic in February 2026, followed one of the largest real-world evidence studies ever conducted for an FDA submission — spanning more than 650,000 women across multiple U.S. health systems.

A newly published randomized clinical trial in The Lancet’s eClinicalMedicine demonstrates that an AI-enabled “digital twin” decision support tool powered by PhenOM®, OM1’s foundational AI model, significantly improves treatment decision quality, shared decision-making, and long-term outcomes for patients with knee osteoarthritis (OA).

OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced that its Rheumatoid Arthritis (RA) specialty dataset achieved the highest quality score in an independent, AI-powered evaluation conducted by Cornerstone AI, a trusted authority in healthcare data quality. The automated evaluation measured OM1’s dataset across three key dimensions: standardization, correctness, and completeness, finding strong performance across the board. To streamline future assessments, the organizations also entered a strategic partnership and established a legal framework to simplify and expedite access to Cornerstone AI’s software for sponsors interested in exploring OM1 data assets.

OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the expansion of its Neurology Specialty Network with the addition of 500,000 patients. The network now includes over 3 million individuals with electronic health records and notes from relevant specialists, making it one of the largest and most clinically rich neurology real-world data resources available.

OM1, the leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, today announced the appointment of Hunter Lane as Chief Product Officer. In this role, Lane will lead the company’s Product and Engineering teams, overseeing the development and delivery of OM1’s rapidly growing portfolio of AI-driven evidence and outcomes solutions.

OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its kind to date.

OM1:

OM1, the leader in real-world data and AI-driven insights for mental health, today announced a significant expansion of its specialty mental health network, adding over one million patients, making it the largest, most clinically rich network of its kind. This milestone deepens OM1’s ability to power high-quality, representative, and timely real-world evidence (RWE) to support better decision-making in life sciences and healthcare.

OM1, a leading provider of real-world data (RWD) and AI-driven insights for life sciences, today announced its expansion into Europe to better support pharmaceutical and healthcare organizations with high-quality, AI-enhanced real-world evidence (RWE) solutions. This step marks a significant milestone in OM1’s mission to improve healthcare decision-making by providing more actionable, data-driven insights across a wider geographic area.

OM1, the leader in real-world evidence generation and insights for life sciences, proudly announces the appointment of Catherine Richards, PhD, MPH, as its first President. Richards will oversee the Product, Engineering, Clinical Informatics, Client Services, Data Science, and Research teams. Her leadership will be pivotal in advancing OM1’s strategy, innovation, and collaboration to improve patient outcomes.

OM1, the leader in real-world insights synthesis and evidence generation for life sciences supporting population and personalized data insights, evidence generation through advanced validated AI platforms, big deep clinical data, registries, and globally recognized thought leadership today announced the new release of its Alzheimer’s disease PremiOM dataset. OM1 combines multiple real-world data sources – including specialists’ electronic medical records (EMR), medical and pharmacy claims, social determinants of health (SDoH), and mental health assessments – with medical language processing and advanced AI capabilities to generate deep clinical insights for patients with Alzheimer’s disease.

OM1, the leader in delivering first-in-class RWE technological advancements and AI-powered insights; today, launches its Registries Center of Excellence (CoE). Dr. Richard Gliklich, CEO and founder of OM1, and Michelle Leavy, Senior Director of Registries, have established a center featuring a cohort of experts offering unparalleled expertise and consultation.

OM1 introduces three new products: OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research. OM1 is the leader in providing Real-World Evidence (RWE) insights from bench to bedside, leveraging advanced predictive and generative AI platforms coupled with deep clinical data to empower healthcare stakeholders.

OM1, the leading AI and insights-driven technology and data company specializing in personalized medicine, evidence generation, and real-world evidence, today announced results from its partnership with Medtronic to investigate the PROPELTM family of devices – corticosteroid-eluting, bioabsorbable implants. The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS). The research aimed to prove that PROPEL devices are associated with reduced HCRU and surgical revisions after sinus surgery, with the goal of using that data to communicate with payers and expand coverage for the implants.

OM1:

OM1, a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma. Both datasets are derived from longitudinal follow-up of patients seen by specialists and focus on patient characteristics, symptoms, treatments, clinical outcomes and healthcare resource utilization. Rapidly growing, the CRS and Asthma datasets each follow approximately 500,000 patients in the U.S.

OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS), a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records.

OM1, a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the appointment of Shawn Bates as Chief Commercial Officer. Bates will work cross-functionally to steer OM1’s commercial strategy – including sales, marketing, and commercial operations – widening the company’s reach across the healthcare and life sciences industries. His efforts will further OM1’s goal to provide deeply rooted, high quality, real-world data and evidence to accelerate research, drive new treatment insights and improve clinical decision making.

OM1, the leading real-world data and technology company focused on chronic conditions, today announced the launch of its Parkinson’s Disease (PD) premium dataset and the enhancement of its Mental Health & Neuroscience Real-World Data Network.

OM1, a leading real-world data and technology company with a focus on chronic conditions, today announced the launch of OM1 Aspen, its novel, automated study platform for evidence generation. OM1 Aspen is a comprehensive offering that is distinguished by the company’s proprietary data sourcing, processing, and enrichment technologies – including electronic medical records harmonization, image management, advanced medical text processing and linkage – to deliver a more efficient, cost-effective, and scalable approach to research.

OM1, a leading real-world data, outcomes, and technology company with a focus on chronic conditions, today announced the launch of two new Real-World Analytics products – Prescriber Trends and Comparative Outcomes – to provide standardized, ready-to-access analyses of trends in treatment and outcomes in immunology and mental health condition areas. Along with OM1’s Reasons for Discontinuation (RfD) Analytic product, launched this past February, the company offers a complementary suite of products that allows stakeholders across the healthcare industry to obtain highly valuable insights on patient and provider behaviors.

OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the expansion of its lupus dataset, PremiOM™ SLE. The enhancement doubles the patient data counts to more than 56,000 Systemic Lupus Erythematosus (SLE) patients with deep clinical data and expands the OM1 Immunology Real-World Data Network to include patients with Cutaneous Lupus Erythematosus (CLE) and Lupus Nephritis. The dataset enables faster, more cost-effective access to research-grade lupus data for understanding, comparing, and predicting treatment outcomes for patients.

OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligence-powered platform for personalized medicine. Calibrated using OM1’s longitudinal health history datasets, PhenOM uses AI to identify unique digital phenotypes associated with conditions and outcomes and compare patients’ records to them to highlight risks and opportunities. PhenOM powers personalized healthcare insights at scale across the entire healthcare ecosystem, from life science research to point-of-care clinical decision making.

OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the enhancement of its Mental Health and Neuroscience Real-World Data to include schizophrenia and bipolar disorder. By introducing enhanced data from more than 148,000 patients with schizophrenia and bipolar, OM1 paves the way for unmatched clinical depth and novel research insights. The data is part of the larger OM1 Mental Health Network of more than 3 million patients, making it the largest specialty network of its kind in the U.S. It is available now for industry partners to further understand disease progression, patient characteristics, condition subtypes as well as the costs and clinical outcomes of treatments in the real world.

OM1 a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its Reasons for Discontinuation (RfD) Analytic Reports. Leveraging the OM1 Real-World Data CloudTM , Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports contain highly valuable, difficult-to-obtain medication discontinuation trends for bDMARDs, cDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions.